The EML4-ALK L1152R mutation results in an amino acid substitution at position 1152 in ALK, from an L to R. L1152R has been detected in the tumor of a patient with ALK fusion-positive lung cancer who developed acquired resistance to the dual ALK/MET TKI crizotinib [86]. Here, ALK is linked to lung cancer.